Drug Approval | December 23, 2025
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Subscribe To Our Newsletter & Stay Updated
